Richard H Ko1,2, Tamekia L Jones3, David Radvinsky4, Nathan Robison1,2, Paul S Gaynon1,2, Eduard H Panosyan5, Ioannis A Avramis1, Vassilios I Avramis1,2, Joan Rubin6, Lawrence J Ettinger7, Nita L Seibel8, Girish Dhall1,2. 1. Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California. 2. Keck School of Medicine, University of Southern California, Los Angeles, California. 3. Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. 4. State University of New York of New York Downstate Medical Center, Brooklyn New York. 5. Division of Pediatric Hematology and Oncology, Harbor-University of California Los Angeles Medical Center, Torrance, California. 6. Department of Pediatrics, St. Peter's University Hospital, New Brunswick, New Jersey. 7. Children's Oncology Group, Monrovia, California. 8. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.
Abstract
BACKGROUND: The objectives of this study were to assess the incidence of clinical allergy and end-induction antiasparaginase (anti-ASNase) antibodies in children with high-risk acute lymphoblastic leukemia treated with pegylated (PEG) Escherichia coli ASNase and to determine whether they carry any prognostic significance. METHODS: Of 2057 eligible patients, 1155 were allocated to augmented arms in which PEG ASNase replaced native ASNase postinduction. Erwinia chrysanthemi (Erwinia) ASNase could be used to replace native ASNase after allergy, if available. Allergy and survival data were complete for 990 patients. End-induction antibody titers were available for 600 patients. RESULTS: During the consolidation phase, 289 of 990 patients (29.2%) had an allergic reaction. There were fewer allergic reactions to Erwinia ASNase than to native ASNase (odds ratio, 4.33; P < .0001) or PEG ASNase (odds ratio, 3.08; P < .0001) only during phase 1 of interim maintenance. There was no significant difference in 5-year event-free survival (EFS) between patients who received PEG ASNase throughout the entire study postinduction versus those who developed an allergic reaction to PEG ASNase during consolidation phase and subsequently received Erwinia ASNase (80.8% ± 2.8% and 81.6% ± 3.8%, respectively; P = .66). Patients who had positive antibody titers postinduction were more likely to have an allergic reaction to PEG ASNase (odds ratio, 2.4; P < .001). The 5-year EFS rate between patients who had negative versus positive antibody titers (80% ± 2.6% and 77.7% ± 4.3%, respectively; P = .68) and between patients who did not receive any ASNase postconsolidation and those who received PEG ASNase throughout the study (P = .22) were significantly different. CONCLUSIONS: The current results demonstrate differences in the incidence rates of toxicity between ASNase preparations but not in EFS. The presence of anti-ASNase antibodies did not affect EFS.
BACKGROUND: The objectives of this study were to assess the incidence of clinical allergy and end-induction antiasparaginase (anti-ASNase) antibodies in children with high-risk acute lymphoblastic leukemia treated with pegylated (PEG) Escherichia coliASNase and to determine whether they carry any prognostic significance. METHODS: Of 2057 eligible patients, 1155 were allocated to augmented arms in which PEG ASNase replaced native ASNase postinduction. Erwinia chrysanthemi (Erwinia) ASNase could be used to replace native ASNase after allergy, if available. Allergy and survival data were complete for 990 patients. End-induction antibody titers were available for 600 patients. RESULTS: During the consolidation phase, 289 of 990 patients (29.2%) had an allergic reaction. There were fewer allergic reactions to ErwiniaASNase than to native ASNase (odds ratio, 4.33; P < .0001) or PEG ASNase (odds ratio, 3.08; P < .0001) only during phase 1 of interim maintenance. There was no significant difference in 5-year event-free survival (EFS) between patients who received PEG ASNase throughout the entire study postinduction versus those who developed an allergic reaction to PEG ASNase during consolidation phase and subsequently received ErwiniaASNase (80.8% ± 2.8% and 81.6% ± 3.8%, respectively; P = .66). Patients who had positive antibody titers postinduction were more likely to have an allergic reaction to PEG ASNase (odds ratio, 2.4; P < .001). The 5-year EFS rate between patients who had negative versus positive antibody titers (80% ± 2.6% and 77.7% ± 4.3%, respectively; P = .68) and between patients who did not receive any ASNase postconsolidation and those who received PEG ASNase throughout the study (P = .22) were significantly different. CONCLUSIONS: The current results demonstrate differences in the incidence rates of toxicity between ASNase preparations but not in EFS. The presence of anti-ASNase antibodies did not affect EFS.
Authors: M H Woo; L J Hak; M C Storm; J T Sandlund; R C Ribeiro; G K Rivera; J E Rubnitz; P L Harrison; B Wang; W E Evans; C H Pui; M V Relling Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: L B Silverman; R D Gelber; V K Dalton; B L Asselin; R D Barr; L A Clavell; C A Hurwitz; A Moghrabi; Y Samson; M A Schorin; S Arkin; L Declerck; H J Cohen; S E Sallan Journal: Blood Date: 2001-03-01 Impact factor: 22.113
Authors: H J Müller; R Beier; L Löning; R Blütters-Sawatzki; W Dörffel; E Maass; S Müller-Weihrich; H G Scheel-Walter; F Scherer; K Stahnke; M Schrappe; A Horn; K Lümkemann; J Boos Journal: Br J Haematol Date: 2001-09 Impact factor: 6.998
Authors: Vassilios I Avramis; Susan Sencer; Antonia P Periclou; Harland Sather; Bruce C Bostrom; Lewis J Cohen; Alice G Ettinger; Lawrence J Ettinger; Janet Franklin; Paul S Gaynon; Joanne M Hilden; Beverly Lange; Fataneh Majlessipour; Pracad Mathew; Michael Needle; Joseph Neglia; Gregory Reaman; John S Holcenberg; Linda Stork Journal: Blood Date: 2002-03-15 Impact factor: 22.113
Authors: Lynda M Vrooman; Jeffrey G Supko; Donna S Neuberg; Barbara L Asselin; Uma H Athale; Luis Clavell; Kara M Kelly; Caroline Laverdière; Bruno Michon; Marshall Schorin; Harvey J Cohen; Stephen E Sallan; Lewis B Silverman Journal: Pediatr Blood Cancer Date: 2010-02 Impact factor: 3.167
Authors: A Masurekar; C Fong; A Hussein; T Revesz; P M Hoogerbrugge; S Love; C Ciria; C Parker; S Krishnan; V Saha Journal: Blood Cancer J Date: 2014-04-25 Impact factor: 11.037
Authors: Yiwei Liu; Colton A Smith; John C Panetta; Wenjian Yang; Lauren E Thompson; Jacob P Counts; Alejandro R Molinelli; Deqing Pei; Nancy M Kornegay; Kristine R Crews; Hope Swanson; Cheng Cheng; Seth E Karol; William E Evans; Hiroto Inaba; Ching-Hon Pui; Sima Jeha; Mary V Relling Journal: J Clin Oncol Date: 2019-06-12 Impact factor: 44.544
Authors: Catherine Mark; Sumit Gupta; Angela Punnett; Julia Upton; Julia Orkin; Adelle Atkinson; Lindsay Clarke; Alice Heisey; Christine McGovern; Sarah Alexander Journal: Pediatr Blood Cancer Date: 2021-08-16 Impact factor: 3.838
Authors: Rachid Abaji; Vincent Gagné; Chang Jiang Xu; Jean-François Spinella; Francesco Ceppi; Caroline Laverdière; Jean-Marie Leclerc; Stephen E Sallan; Donna Neuberg; Jeffery L Kutok; Lewis B Silverman; Daniel Sinnett; Maja Krajinovic Journal: Oncotarget Date: 2017-07-04